- Opinion
- [FOCUS] Pharmaceutical bio-industry in the Middle of Change
- by Kim, Jung-Ju Jan 8, 2020 08:10pm
- This year, the Ministry of Health and Welfare increased the pharmaceutical bio industry support budget by two digits in each sector. The AI &8203;&8203;drug development platform construction support division has successfully allocated &8361;2.8 billion, up &8361;300 million (11.1%) from last year's &8361;2.5 billion, and support for t
- Opinion
- [Reporter’s View] At least a guideline for ‘class effect’
- by Eo, Yun-Ho Jan 3, 2020 06:33am
- ‘Recognizing expected efficacy of drugs with same mechanism of action.’ It is definitely an unresolved conundrum. Experts have clashing opinions and each pharmaceutical company has different interests. In the end, what it comes down to is ‘case by case.’ Not that it needs an answer key, but obviously the prescribing doctor’s decis
- Opinion
- [Reporter’s View] Next year wishes for the industry
- by An, Kyung-Jin Dec 30, 2019 09:47pm
- “Last year, not one of Korean-made new drug was approved by the U.S. Food and Drug Administration (FDA). Ever since hemophilia treatment Aftyla was passed in 2016, Korean drugs have not been able to get a green light from the U.S. health regulator for two consecutive years. However, the industry is expected to bring a series of good news th
- Opinion
- [FOCUS] There is no reliability of cluless government policy
- by Chon, Seung-Hyun Dec 26, 2019 06:29am
- The impurity issues that started in Valsartan last summer led to Ranitidine and Nizatidine, and many drug products were discontinued. This year, the domestic pharmaceutical industry suffered greatly due to impurity risk all year round. Using a stigma called "carcinogen", a huge amount of medicines were recovered, and pharmaceutical companies
- Opinion
- [Column] Self-injectable drug abuse, is SPD the answer?
- by Kim, Jung-Ju Dec 17, 2019 01:40am
- Self-injectable obesity treatment Saxenda has been under fire constantly, because the obesity treatment has been abused as a weight management injection generating not only safety concerns but also questionable profit for the interest group. Apparently, the government said it would provide answer to it in November. Some likely suggestion
- Opinion
- [Reporter's view] Illegal Rebate CSO
- by Lee, Jeong-Hwan Dec 11, 2019 06:40am
- I suddenly thought that the trifoliate orange is innocent when I was covering the law revision extending medical and pharmacological expenditure reports to pharmaceutical CSOs. Pharmaceutical industry ethics management (CP) experts refer to CSOs based on drug expertise as tangerines, the CSO which was altered as an illegal rebate, as trifo
- Opinion
- [FOCUS]Post-evaluation necessity & task for reimbursed drugs
- by Kim, Jung-Ju Dec 11, 2019 06:39am
- As the health insurance coverage is strengthened as social insurance, value judgment becomes a very important policy task for the efficiency of payment and payment. Among them, the weight of medicines has changed along with the coverage. In the past, under the negative list system, the value of drug insurance was focused on listing more dr
- Opinion
- [Column] The inconvenient truth of ATP survey
- by Eo, Yun-Ho Dec 9, 2019 06:29am
- The next round of biennial actual transaction price (ATP)-based drug price reduction is to be in effect from January 2020. It feels like the time is approaching too fast too soon. While going through hectic times with the aftermath of valsartan and ranitidine incidents, affected pharmaceutical companies, distributors and healthcare insti
- Opinion
- Both to blame of the rising Pharmaceuticals & Korea
- by Eo, Yun-Ho Dec 5, 2019 06:16am
- The pharmaceutical industry is a high value-added industry and Korea is now more interested in new drugs than ever before. As interest has increased, the names of pharmaceutical companies that have reported news such as clinical failures, discontinuations, or controversy about efficacy are very popular on the Internet. It is possible. S
- Opinion
- [Column] Legal disputes over rebate penalty reducing price
- by Lee, Hye-Kyung Dec 5, 2019 06:12am
- This year would be a year to remember as various issues regarding drug pricing broke out, such as ‘lump-sum price reduction on single-use eye drops’, ‘revised generic pricing system’, and ‘litigation against pricing reduction penalty for providing rebate’. Currently the drug pricing system is geared towards paradigm shift, starting
